South America Ovarian Cancer Diagnostics and Therapeutics Market - Segmented by Type of Cancer and Geography 2017 - 2022

  • ID: 4388329
  • Report
  • Region: South America
  • 121 pages
  • Mordor Intelligence
1 of 4
The Latin American market for ovarian cancer diagnostics and therapeutics accounted for USD 44 million in 2015 and is anticipated to grow at a CAGR of 10-16% till 2020.

Ovarian cancer is caused by an uncontrollable cell growth in the ovarian tissue. It is a growing concern, as it is one of the most common causes of death in women across the globe. Thereby, the need to develop new medication and therapies for the effective treatment of this disease, and new methods for the timely diagnosis of ovarian cancer is increasing. Thus the market for ovarian cancer diagnostics and therapeutics is at a stage of huge development.

The market for ovarian cancer diagnostics and therapeutics is segmented on the basis of:

Type

Epithelial ovarian tumors

Ovarian germ cell tumors

Ovarian stromal tumors

Primary peritoneal carcinoma

Cancer stage

Stage I

Stage II

Stage III

Stage IV

Diagnosis

Physical examination

Biopsy

Blood tests

Human Chorionic Gonadotropin (hCG) test

Ultrasound

MRI

PET

CT scans

Treatment

Chemotherapy

Localized ovarian cancer therapeutics

Metastatic ovarian cancer therapeutics

Recurrent ovarian cancer therapeutics

Targeted therapy

Radiation therapy

Immunotherapy

Hormonal therapy

Surgery

Geography

Some of the major companies operating in the ovarian cancer market are Bristol Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, Janssen Pharmaceuticals, Inc., Novogen, Inc., Genentech Inc., Astra Zeneca, Boehringer Ingelheim GmbH and F. Hoffman-La Roche Ltd.

Drivers

Increasing incidences of ovarian cancer worldwide

Increasing population of aged women

Greater use of combination therapies for the treatment

Increase in healthcare expenditure

Increased government funding

Increasing healthcare awareness

Restraints

Launch of generic drugs

Patent expiry of key drugs

Lack of accurate diagnosis of ovarian cancer

SPECIALITIES OF THIS REPORT

The report will be useful in gaining an exhaustive understanding of the regional market. It will also be of assistance in providing a comprehensive analysis of the major trends, innovations and associated prospects for market growth over the coming half a decade.

The report will be an ideal source material for industry consultants, manufacturers and other interested and allied parties to gain a critical insight into the factors driving and restraining the market, in addition to opportunities offered.

The report contains wide range of information about the leading market players and the major strategies adopted by them.

WHAT THE REPORT OFFERS

Market definition along with identification of key drivers and restraints for the market.

Market analysis with region specific assessments and competition analysis on a global and regional scale.

Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies, which can influence the market on a global and regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market shares.

Identification and analysis of the macro and micro factors that affect the industry on both global and regional scale.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
READ MORE
Note: Product cover images may vary from those shown
2 of 4
1. Introduction
1.1 Report Description
1.2 Research Methodology
2. Executive Summary
3. Market Overview
3.1 Market Definition
3.2 Market Drivers
3.2.1 Increasing incidences of ovarian cancer
3.2.2 Aging population of women
3.2.3 Greater use of combination therapies for the treatment of Ovarian cancer
3.2.4 Increase in healthcare expenditure
3.2.5 Increased government funding
3.2.6 Increasing healthcare awareness
3.3 Market restraints
3.3.1 The launch of generic drugs
3.3.2 Patent expiry of key drugs
3.3.3 Lack of accurate diagnosis of ovarian cancer
3.4 Market Opportunitites
3.5 Market Threats
4. Porters Five Force Analysis
4.1 Bargaining Power of suppliers
4.2 Bargaining power of buyers
4.3 Degree of competition
4.4 Threat of substitution
4.5 Threat of new entrants
5. Market Segmentation
5.1 By Cancer Type
5.1.1 Epithelial ovarian tumors
5.1.2 Ovarian germ cell tumors
5.1.3 Ovarian stromal tumors
5.1.4 Primary Peritoneal Carcinoma
5.2 By Cancer stage
5.2.1 Stage I
5.2.1.1 Stage IA
5.2.1.2 Stage IB
5.2.1.3 Stage IC
5.2.2 Stage II
5.2.2.1 Stage IIA
5.2.2.2 Stage IIB
5.2.2.3 Stage IIC
5.2.3 Stage III
5.2.3.1 Stage IIIA
5.2.3.2 Stage IIIB
5.2.3.3 Stage IIIC
5.2.4 Stage IV
5.3 Diagnosis
5.3.1 Physical Examination
5.3.2 Biopsy
5.3.3 Blood Tests
5.3.4 Human Chorionic Gonadotropin (hCG) Test
5.3.5 Ultrasound
5.3.6 MRI
5.3.7 PET
5.3.8 CT Scan
5.4 Treatment
5.4.1 Chemotherapy
5.4.1.1 Localized ovarian cancer therapeutics
5.4.1.2 Metastatic ovarian cancer therapeutics
5.4.1..3 Recurrent ovarian cancer therapeutics
5.4.2 Targeted therapy
5.4.3 Radiation Therapy
5.4.4 Immunotherapy
5.4.5 Hormonal therapy
5.4.6 Surgery
5.5 By Geography
5.5.1 Latin America
5.5.1.1 Mexico
5.5.1.2 Brazil
5.5.1.3 Argentina
6. Competitive Landscape
7. Company Profiles
7.1 Bristol Myers Squibb Company
7.2 Eli Lilly and Company
7.3 GlaxoSmithKline plc
7.4 Janssen Pharmaceuticals, Inc.
7.5 Novogen, Inc.
7.6 Genentech Inc.
7.7 Astra Zeneca
7.8 Boehringer Ingelheim GmbH
7.9 F. Hoffman-La Roche Ltd
8. Appendix
8.1 Abbrevations
8.3 Bibliography
8.4 Disclaimer
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll